Enamel Remineralization Potential of Dentifrices in Situ

NCT ID: NCT01128946

Last Updated: 2015-01-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-11-30

Study Completion Date

2010-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will use an oral in-situ caries model to study remineralization of enamel due to the action of different combinations of fluoride salts delivered from dentifrices.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dental Caries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Fluoride Toothpaste 1

Fluoride toothpaste containing sodium fluoride (NaF)

Group Type EXPERIMENTAL

NaF

Intervention Type DRUG

Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

Fluoride Toothpaste 2

Fluoride toothpaste containing stannous fluoride (SnF) and NaF.

Group Type EXPERIMENTAL

NaF

Intervention Type DRUG

Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

SnF

Intervention Type DRUG

Fluoride toothpaste containing stannous fluoride (1100 ppmF)

Fluoride Toothpaste 3

Fluoride toothpaste containing sodium monofluorophosphate (NaMFP) and NaF.

Group Type EXPERIMENTAL

NaF

Intervention Type DRUG

Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

NaMFP

Intervention Type DRUG

Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)

Reference Dentifrice

Low fluoride toothpaste containing NaF

Group Type ACTIVE_COMPARATOR

NaF

Intervention Type DRUG

Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NaF

Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.

Intervention Type DRUG

SnF

Fluoride toothpaste containing stannous fluoride (1100 ppmF)

Intervention Type DRUG

NaMFP

Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Good general health with (in the opinion of the investigator) no clinically significant and relevant abnormalities of medical or oral health.
* No current active caries or periodontal disease that may compromise the study or health of the subject.
* All restorations in a good state of repair
* Currently wearing a removable mandibular partial denture with sufficient room in the posterior buccal flange area to accomodate two enamel specimens required dimensions 12 x 7 mm.
* Willing to have their denture modified to accomodate enamel test specimens
* Willing and capable of wearing removable mandibular partial dentures 24 hours per day during the treatment periods.
* Salivary flow rate in the range of normal values (unstimulated whole saliva flow rate greater than or equal to 0.2 mL/ minute; gum base stimulated whole saliva flow rate greater than or equal to 0.8 mL/minute.

Exclusion Criteria

* Individuals currently taking antibiotics, or who have taken antibiotics within 30 days prior to the first treatment visit.
* Current active caries or periodontal disease that may compromise the study or health of the subject.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GlaxoSmithKline

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Indiana University School of Dentistry

Indianapolis, Indiana, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

T3500690

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

In Situ Caries of Fluoride Toothpastes
NCT00708123 COMPLETED PHASE3